Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

Investors without a scientific background can de-risk biotech portfolios by avoiding early-stage "science projects" (Phase 1-2). Instead, they should focus on companies that have completed Phase 3 trials. This strategy shifts the primary risk from unpredictable scientific development to more analyzable commercial execution.

For early-stage biotech companies, saving money by limiting initial drug substance characterization is a false economy. A comprehensive, state-of-the-art characterization before Phase 1 is essential to de-risk the program by identifying molecular issues before they become catastrophic problems in late-stage development.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

Resolution Therapeutics' CEO warns that manufacturing process changes cannot wait for pivotal trials in cell therapy. The drug product used in a Phase 1/2 study must be highly comparable to the final commercial version to avoid extremely costly delays and extensive comparability studies later in development.

A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.